January 19, 2009. Dr. David Barker joins the Scientific Advisory Board of BiOptix LLC

Contact: Misha Plam,
CEO,
BiOptix LLC
(303) 641-3669
m.plam@comcast.net
http://www.BiOptix.com

Boulder, Colorado, January 19, 2009.

BOULDER, CO, January 19, 2009 /PRNewswire/ - Boulder, Colorado, January 19, 2009. BiOptix LLC, a privately held company developing a new technology for rapid, sensitive, label-free detection of biomarkers, today announced that Dr. David Barker has joined the Company’s Scientific Advisory Board.

From 2000 through 2006 Dr. Barker was Vice President and Chief Scientific Officer at Illumina, Inc., in San Diego, California, a leading developer of genomic analysis systems. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. He serves on the Boards of Directors of NextBio, Cell Biosciences, and Microchip Biotechnologies, Inc.

In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

“BiOptix has developed a very elegant label-free detection system for molecular binding interactions. It is more sensitive than surface plasmon resonance and more amenable to array configurations” said Dr. Barker. “I look forward to assisting the company in refining the product for launch in 2009.”

“David’s deep knowledge of the industry will be of great value in helping identify applications in which BiOptix can create unique value for our customers,” said Dr. Misha Plam, Founder and CEO of BiOptix. “Now that we are moving to commercialization of the technology, David will provide tremendous insight and focus as we move into our selected markets.”

BiOptix, established in 2003, has developed a proprietary technology for real-time, sensitive, label-free detection of medically and commercially important molecules such as DNA, proteins, toxins, contaminants and other molecules. Applications using this broad technology platform include real-time detection instruments for the medical research, personalized medicine and medical diagnostics markets, pharmaceutical process control, the defense and homeland security markets, and other industrial applications. The core technology, known as SPE/CPI, was invented at BiOptix by Dr. John Hall, 2005 Nobel Prize Laureate in Physics, Slava Petropavlovskikh, and Dr. Oyvind Nilsen. The company will launch a four channel instrument at Pittcon 2009 in March.

Link to the original press release